13F HOLDINGS REPORT
GILEAD SCIENCES, INC.
Quarter ended Q4 2025 · Filed February 12, 2026 · Accession 0001123292-26-000164
Total Value
$1.94B
Positions
6
Other Managers
1
Confidential Omitted
No
Holdings (6)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | ARCUS BIOSCIENCES INC | RCUS | 31,424,760 | $748.9M | 38.69% |
| 2 | GALAPAGOS NV | GLPGF | 16,707,477 | $550.6M | 28.45% |
| 3 | ARCELLX INC | ACLX | 6,720,803 | $438.2M | 22.64% |
| 4 | ASSEMBLY BIOSCIENCES INC | ASMB | 4,505,391 | $153.2M | 7.92% |
| 5 | KYVERNA THERAPEUTICS INC | KYTX | 4,126,119 | $38.8M | 2.00% |
| 6 | XILIO THERAPEUTICS INC | XLO | 9,105,451 | $5.8M | 0.30% |